RBC Capital analyst Luca Issi lowered the firm’s price target on Moderna (MRNA) to $25 from $28 and keeps a Sector Perform rating on the shares after its Analyst Day presentation. Vaccination rates are down 28% this year, but Moderna sees their top-line re-inflecting next year driven by COVID contracts ex-US and the uptake of their next-gen COVID vaccine, the analyst tells investors in a research note. RBC adds that while it appreciates all the progress and an organization that is now much more focused on managing costs, the firm remains on the sideline awaiting further clarity on top-line re-inflection.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Cautious Outlook on Moderna: Debt Reliance and Modest Growth Amidst Legal Challenges
- Moderna price target raised to $18 from $15 at Leerink
- Moderna price target lowered to $63 from $69 at Piper Sandler
- Cautious Hold on Moderna Amid Strategic Pipeline Shift and Financial Uncertainty
- Moderna’s Strategic Growth and Financial Outlook: Buy Rating Affirmed by Analyst David Dai